Guardant Health's Shield Blood Test Achieves 99% Screening Adherence in Rural Clinic Study

Guardant Health presented Shield colorectal cancer blood test research at the American College of Gastroenterology's 2026 annual meeting in Nashville. A lifetime modeling study projected blood-based screening would avert more colorectal cancer deaths than stool-based tests while increasing colonoscopy use. A separate study at two rural South Carolina clinics found high screening adherence, supporting Shield's potential to expand screening in underserved communities. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via (Ref. ID: 20261015639865) on October 15, 2026, and is solely responsible for the information contained therein. (C)